CDT CDT Equity Inc. stock chart & analysis
Conviction 45HealthcareScan · Fri, Nov 6, 2026CDT Equity Inc. (CDT) closed at $1.28 (+2926.00%) on Nov 6, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 33, RS Rating 1, -100.0% from its 52-week high, -100.0% year to date. Sector: Healthcare · Pharmaceutical Preparations.
Why CDT moved
From the StockSetups movers recaps that covered CDT, newest first. A recap states what was known that day.
- Close+2926.0%
CDT closed up 2,926.0% at $1.28 on 60,120,530 shares, against a 20-day average of about 25.3 million. It gapped up 3,186.0% at the open. A gap is when a stock opens far from the prior close. Market cap was only about $34K.
Top Stock Movers Nov 6, 2026: Why CDT, STAK, GOGO Surged →
Financials as of Tue, Jun 30, 2026 · quarterly.
CDT technical analysis
Trend
CDT is in a downtrend: price is below the 50-day, which is below the 200-day moving average. It closed 77.1% below the 50-day ($5.59) and 99.9% below the 200-day ($1,318.04). ADX(14) at 54 points to a strong, established trend. It meets 1 of 8 trend-template criteria.
Momentum
RSI(14) is 33, in the bearish half of its range. The MACD histogram is positive. Its RS Rating of 1 puts its weighted 12-month performance ahead of about 1% of the US market.
Volume and volatility
Volume on the latest session ran 2.7× its 20-day average. It trades about $5.8M a day on average. ATR(14) is $0.6770, 52.9% of price — its typical daily range. Bollinger Bands are in a squeeze (23 sessions) — volatility is compressed. On-balance volume is trending up. Chaikin Money Flow (0.30) shows accumulation.
Key levels
The chart pattern's support is $0.0390 and its resistance $0.1737. The 52-week range is $0.0390 to $17,040.00; price is 100.0% below the high and 3182.0% above the low. The VWAP anchored at the 52-week high is $1.62, above price.
Performance
CDT returned +1782.3% (1 week), +60.0% (1 month), -98.4% (3 months), -99.8% (6 months), -100.0% (1 year), -100.0% (year to date).
About CDT Equity Inc.
CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. It has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The company's pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, rare disease and animal health. It has one operating segment focused on the research and development of clinical assets.
Pharmaceutical Preparations · Listed 2023 · 4 employees
Recent news
- Why Is CDT Equity (NASDAQ:CDT) Up 22.91% With No Announcement Found?kalkine.ca · Fri, Nov 6, 2026
- Form 13D/A CDT Equity Inc. For: 6 November By Investing.comInvesting.com Canada · Fri, Nov 6, 2026
- CDT Equity schedules 1-for-20 reverse stock split effective this weekInvesting.com · Wed, Nov 4, 2026
- Form 8K CDT Equity Inc For: 4 November By Investing.comInvesting.com India · Wed, Nov 4, 2026
- A reverse split will take effect November 5 at 5 p.m. ET for CDT Equity (CDT).Stock Titan · Wed, Nov 4, 2026
- CDT Equity Inc.: Resale prospectusSEC EDGAR · Wed, Nov 4, 2026
- CDT Equity Inc.: 8-K filedSEC EDGAR · Wed, Nov 4, 2026
- CDT Equity (CDT) Stock Forecast & Analyst RatingsMoomoo · Mon, Nov 2, 2026
- CDT Equity (CDT) Income Statement & EarningsMoomoo · Sun, Nov 1, 2026
Insider activity
SEC Form 4 transactions in CDT · open-market 2 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Regan Andrew 10% owner · Common Stock · 2026-10-23 | Acquire | 499.62K | — | 2026-10-23 | 2026-10-27 |
Regan Andrew 10% owner · Common Stock · 2026-10-22 | Acquire | 1.35M | — | 2026-10-22 | 2026-10-27 |
Regan Andrew Chief Executive Officer · Common Stock · 2026-08-28 | Acquire | 543.68K | — | 2026-08-28 | 2026-10-27 |
Regan Andrew Chief Executive Officer · Common Stock · 2026-08-28 | Sell | 29 | — | 2026-08-28 | 2026-10-27 |
Regan Andrew Chief Executive Officer · Pre-Funded Warrants · 2026-08-28 | Exercise | 543.68K | $54 | 2026-08-28 | 2026-10-27 |
Regan Andrew Chief Executive Officer · Pre-Funded Warrants · 2026-07-30 | Acquire | 5.44M | $544 | 2026-07-30 | 2026-10-27 |
Regan Andrew Chief Executive Officer · Common Stock · 2026-08-28 | Sell | 290 | — | 2026-08-28 | 2026-09-02 |
Regan Andrew Chief Executive Officer · Common Stock · 2026-08-28 | Acquire | 5.44M | — | 2026-08-28 | 2026-09-02 |
Regan Andrew Chief Executive Officer · Pre-Funded Warrants · 2026-08-28 | Exercise | 5.44M | $544 | 2026-08-28 | 2026-09-02 |
Regan Andrew Chief Executive Officer · Pre-Funded Warrants · 2026-07-30 | Acquire | 5.44M | $544 | 2026-07-30 | 2026-09-02 |
SEC filings
EDGAR filings in CDT · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.